Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes on OPKO, Synageva, Hill-Rom, Anacor, and

 Supply Agreements, Patents, Appointments, and FDA Clearances - Analyst Notes
       on OPKO, Synageva, Hill-Rom, Anacor, and Cardiovascular Systems

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 20, 2014

NEW YORK, March 20, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding OPKO Health,
Inc. (NYSE: OPK), Synageva BioPharma Corp. (NASDAQ: GEVA), Hill-Rom Holdings,
Inc. (NYSE: HRC), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), and
Cardiovascular Systems Inc. (NASDAQ: CSII). Private wealth members receive
these notes ahead of publication. To reserve complementary membership, limited
openings are available at:


On March 10, 2014, OPKO Health, Inc. (OPKO) reported that one of its
divisions, OPKO Diagnostics, has signed a supply agreement with Sony DADC for
high volume production of a key component of the OPKO Sangia™ microfluidic
cassette. The Company informed that the Sangia cassettes are designed to
perform quantitative immunoassays from a finger-stick blood sample on the
Claros®1 in-office analyzer. Commenting on the agreement, David Okrongly,
President of OPKO Diagnostics, stated, "We are pleased to be partnered with
Sony DADC, a world leader in high precision consumable manufacturing, for
production of Sangia technology components. It is critical to us that Sony
DADC also meets the regulatory demands of our in vitro diagnostic products and
is manufacturing to the ISO 13485 quality standard." The Company added that
Sony DADC BioSciences is using ISO 13485 facility in Salzburg, Austria to
manufacture to OPKO Diagnostics' specifications. The full analyst notes on
OPKO Health, Inc. are available to download free of charge at:


On March 4, 2014, Synageva BioPharma Corp. (Synageva) announced that the U.S.
Patent and Trademark Office issued U.S. Patent No. 8,663,631 covering methods
of treating lysosomal acid lipase deficiency (LAL Deficiency). According to
the Company, the patent provides protection until 2031, not including any
patent term extension, and complements Synageva's existing and planned global
patent portfolio covering its LAL Deficiency program, which includes
intellectual property directed to composition of matter, methods of use, and
manufacturing. The full analyst notes on Synageva BioPharma Corp. are
available to download free of charge at:


On March 10, 2014, Hill-Rom Holdings, Inc. (Hill-Rom) announced the election
of William G. Dempsey to the Company's Board of Directors. The Company stated
that Mr. Dempsey currently serves as a director of Landauer, Inc., Nordion
Inc., and Hospira, Inc., and previously held various executive positions with
Abbott Laboratories. Commenting on the appointment, Rolf A. Classon, Chairman
of the Hill-Rom Board of Directors, stated, "Bill has a wealth of experience
in the health care industry that will further strengthen our Board. His broad
senior level executive, international and operational experience will serve
our shareholders and Board well." The full analyst notes on Hill-Rom Holdings,
Inc. are available to download free of charge at:


On March 10, 2014, Anacor Pharmaceuticals, Inc. (Anacor) announced that it has
appointed Vince Ippolito as the Company's Executive Vice President and Chief
Commercial Officer. David Perry, CEO of Anacor, commented, "We are very
excited to have Vince join our team as Chief Commercial Officer. His extensive
experience in launching new products and leading sales and marketing efforts
to specialty physicians will be invaluable as we develop a commercial strategy
for tavaborole and AN2728." The Company informed that Mr. Ippolito has over 25
years of experience in leading specialty medical sales and marketing efforts
at Valeant Pharmaceuticals, Inc., Medicis Pharmaceutical Corporation, and
Novartis AG. The full analyst notes on Anacor Pharmaceuticals, Inc. are
available to download free of charge at:


On March 10, 2014, Cardiovascular Systems Inc. (Cardiovascular Systems)
announced that it has obtained FDA clearance of its Diamondback 360® 60cm
Peripheral Orbital Atherectomy Systems (OAS) for treating peripheral arterial
disease (PAD). Commenting on the clearance, David L. Martin, Cardiovascular
Systems President and CEO, stated, "Receiving FDA clearance for our new 60cm,
4 French (4 Fr) devices demonstrates CSI's commitment to advancing technology
and expanding the interventional market. Our new 60cm Diamondback devices are
compatible with 4 Fr introducer sheaths. The use of smaller sheaths has been
shown to reduce procedure times, enable quicker patient recovery and have less
procedural complications from bleeding, providing additional procedural
benefits to patients and physicians." The full analyst notes on Cardiovascular
Systems Inc. are available to download free of charge at:

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.



  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oForanyurgentconcernsorinquiries, please contact us at compliance
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +1-852-8191-3972
Press spacebar to pause and continue. Press esc to stop.